InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,312.22
(
0.35%
)
Post# of 252301
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 119891
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 205388

Friday, 02/03/2017 1:45:27 PM

Friday, February 03, 2017 1:45:27 PM

Post# of 252301
Keytruda monotherapy has 6/14/17 PDUFA in separate sBLAs for first- and second-line bladder cancer:

https://finance.yahoo.com/news/fda-accepts-two-sblas-merck-114500611.html

The first-line sBLA is for patients ineligible for platinum chemo and is based on the single-arm KEYNOTE-052 study. The second-line sBLA is based on the KEYNOTE-045 syudy, which compared Keytruda monotherapy to “investigator’s choice” chemo.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up